Identifying Patients with Early-Stage Triple-Negative Breast Cancer Who Can Safely Avoid Chemotherapy Based on Stromal Tumor-Infiltrating Lymphocyte Levels
Patients with stage I triple-negative breast cancer (TNBC) who have high levels of stromal tumor-infiltrating lymphocytes (TILs) demonstrate excellent 10-year breast cancer-specific survival without chemotherapy, suggesting stromal TILs could be a useful biomarker to optimize treatment decisions in this patient population.